Icon (NASDAQ:ICLR) Posts Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Icon (NASDAQ:ICLR) posted its earnings results on Tuesday. The medical research company reported $2.66 EPS for the quarter, beating the consensus estimate of $2.62 by $0.04, FiscalAI reports. The company had revenue of $2.02 billion during the quarter, compared to analyst estimates of $2.01 billion. Icon had a return on equity of 8.02% and a net margin of 3.99%.

Icon Stock Performance

ICLR stock traded down $0.80 during trading on Tuesday, reaching $182.98. 889,952 shares of the company’s stock were exchanged, compared to its average volume of 1,245,672. The company has a quick ratio of 0.95, a current ratio of 0.95 and a debt-to-equity ratio of 0.23. Icon has a 1-year low of $66.57 and a 1-year high of $203.91. The company’s fifty day moving average price is $169.15 and its 200-day moving average price is $146.16. The firm has a market cap of $14.01 billion, a PE ratio of 42.95, a P/E/G ratio of 11.98 and a beta of 1.24.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on ICLR shares. William Blair upgraded Icon to a “strong-buy” rating in a research report on Thursday, July 30th. Bank of America raised Icon from an “underperform” rating to a “neutral” rating and set a $185.00 target price on the stock in a research report on Friday, October 9th. Citigroup cut their target price on Icon from $180.00 to $175.00 and set a “neutral” rating on the stock in a research note on Friday, September 18th. Zacks Research raised shares of Icon from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 28th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Icon in a research report on Wednesday, August 26th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Icon presently has a consensus rating of “Hold” and an average price target of $174.73.

Insider Activity at Icon

In other news, CFO Bernard Clerkin sold 2,267 shares of the firm’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $164.29, for a total transaction of $372,445.43. Following the transaction, the chief financial officer directly owned 5,881 shares of the company’s stock, valued at approximately $966,189.49. This trade represents a 27.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Ronan Murphy sold 5,005 shares of Icon stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $175.00, for a total transaction of $875,875.00. Following the sale, the director owned 3,847 shares in the company, valued at approximately $673,225. This represents a 56.54% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 23,068 shares of company stock valued at $3,936,744. 44.00% of the stock is owned by corporate insiders.

Icon News Roundup

Here are the key news stories impacting Icon this week:

• Positive Sentiment: Q3 earnings and revenue exceeded expectations. Icon reported adjusted earnings of $2.66 per share, topping the $2.62 consensus estimate, while revenue of $2.02 billion came in ahead of analysts’ $2.01 billion forecast. Icon Q3 2026 earnings release
• Positive Sentiment: A $24.5 billion backlog and higher buyback signal support the recovery case. The reported backlog provides visibility into future contract-research revenue, while an increased share-repurchase authorization could support per-share earnings and indicate management’s confidence in the business. ICON Q3 2026 earnings and backlog article
• Neutral Sentiment: Insider selling appears routine. Chief Accounting Officer Emer Lyons sold 272 shares worth approximately $49,600 to cover tax withholding tied to vested equity awards. Because the sale was explicitly tax-related and relatively small, it is unlikely to materially alter the investment case. Icon insider transaction report
• Neutral Sentiment: Short-interest data offers little trading signal. Reported short interest was zero, suggesting no meaningful bearish short positioning, although the figure does not itself provide a catalyst.
• Negative Sentiment: Valuation remains demanding. Icon trades at roughly 43 times earnings, while the consensus analyst target of $174.73 is below the recent trading range. That valuation leaves less room for disappointment if growth or margins fail to accelerate.

About Icon

ICON plc is a global contract research organization that provides outsourced development services to pharmaceutical, biotechnology and medical device companies. The company supports clinical research programs from early development through late-stage trials, regulatory submission and post-marketing activities.

Its services include clinical trial management, medical and regulatory consulting, biostatistics, data management, pharmacovigilance, laboratory services and real-world evidence solutions.